Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin and Thalidomide in Advanced Hepatocellular Carcinoma
NCT00058487Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin and thalidomide in hepatocellular carcinoma (HCC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Antitumor activity and Toxic effects. Started Dec 2001; status: completed.
02
Drugs
epirubicinthalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00058487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058487.